All In Biotech

Drug Trial Radar · NCT00006721

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas

Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 571 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

571

Actual

Start

Mar 2001

Primary completion

Sep 2011

Study completion Dec 2025

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibodies given together with combination chemotherapy to see how well they work in treating patients with newly-diagnosed non-Hodgkin's lymphoma.

Conditions

  • Lymphoma

Interventions

  • rituximabBiological

    Given IV

  • cyclophosphamideDrug

    Given IV

  • doxorubicinDrug

    Given IV

  • prednisoneDrug

    Given orally

  • vincristineDrug

    Given IV

  • tositumomabRadiation

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival at 2 YearsTime frame: 0-2 years
  2. Progression-free Survival at 5 YearsTime frame: 0-5 years
  3. Overall Survival at 2 YearsTime frame: 0-2 years
  4. Overall Survival at 5 YearsTime frame: 0-5 years

Locations

259 sites in 1 country. Site status is shown where the registry gives one.

  • Alaska Regional Hospital Cancer Center

    Anchorage, Alaska

  • Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Hembree Mercy Cancer Center at St. Edward Mercy Medical Center

    Fort Smith, Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Alta Bates Summit Comprehensive Cancer Center

    Berkeley, California

  • Peninsula Medical Center

    Burlingame, California

  • Marin Cancer Institute at Marin General Hospital

    Greenbrae, California

  • Sutter Health - Western Division Cancer Research Group

    Greenbrae, California

  • Desert Regional Medical Center Comprehensive Cancer Center

    Palm Springs, California

  • University of California Davis Cancer Center

    Sacramento, California

  • California Pacific Medical Center - California Campus

    San Francisco, California

  • Stanford Cancer Center

    Stanford, California

  • Sutter Solano Medical Center

    Vallejo, California

  • Helen and Harry Gray Cancer Center at Hartford Hospital

    Hartford, Connecticut

  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Center for Cancer Care and Research at Watson Clinic, LLP

    Lakeland, Florida

  • Sacred Heart Cancer Center at Sacred Heart Hospital

    Pensacola, Florida

  • West Florida Cancer Institute at West Florida Hospital - Pensacola

    Pensacola, Florida

  • Piedmont Hospital

    Atlanta, Georgia

  • Northside Hospital Cancer Center

    Atlanta, Georgia

  • Saint Joseph's Hospital of Atlanta

    Atlanta, Georgia

  • CCOP - Atlanta Regional

    Atlanta, Georgia

  • WellStar Cobb Hospital

    Austell, Georgia

  • Charles B. Eberhart Cancer Center at DeKalb Medical Center

    Decatur, Georgia

  • Dwight David Eisenhower Army Medical Center

    Fort Gordon, Georgia

  • Northeast Georgia Medical Center

    Gainesville, Georgia

  • Gwinnett Medical Center

    Lawrenceville, Georgia

  • Kennestone Cancer Center at Wellstar Kennestone Hospital

    Marietta, Georgia

  • Southern Regional Medical Center

    Riverdale, Georgia

  • Pearlman Comprehensive Cancer Center at South Georgia Medical Center

    Valdosta, Georgia

  • Tripler Army Medical Center

    Honolulu, Hawaii

  • Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center

    Boise, Idaho

  • Mountain States Tumor Institute at St. Luke's Regional Medical Center

    Boise, Idaho

  • Saint Anthony's Hospital at Saint Anthony's Health Center

    Alton, Illinois

  • Rush-Copley Cancer Care Center

    Aurora, Illinois

  • St. Joseph Medical Center

    Bloomington, Illinois

  • Graham Hospital

    Canton, Illinois

  • Memorial Hospital

    Carthage, Illinois

  • University of Illinois Cancer Center

    Chicago, Illinois

  • University of Chicago Cancer Research Center

    Chicago, Illinois

Showing 40 of 259 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.